LivaNova PLC (NASDAQ:LIVN) Receives $83.50 Average Price Target from Brokerages

Shares of LivaNova PLC (NASDAQ:LIVN) have received an average recommendation of “Moderate Buy” from the eleven ratings firms that are currently covering the company, MarketBeat reports. Five equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $83.50.

Several brokerages have commented on LIVN. Freedom Capital upgraded shares of LivaNova to a “hold” rating in a report on Tuesday, June 30th. Robert W. Baird cut their target price on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Barclays boosted their price target on shares of LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a research report on Thursday, May 7th. Needham & Company LLC increased their price target on shares of LivaNova from $81.00 to $93.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Finally, KeyCorp raised their price objective on shares of LivaNova from $83.00 to $92.00 and gave the stock an “overweight” rating in a report on Monday, June 22nd.

Institutional Investors Weigh In On LivaNova

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Hantz Financial Services Inc. increased its stake in shares of LivaNova by 159.9% in the 4th quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock worth $27,000 after acquiring an additional 267 shares in the last quarter. Public Employees Retirement System of Ohio bought a new stake in LivaNova during the second quarter worth about $37,000. State of Wyoming bought a new stake in LivaNova during the second quarter worth about $31,000. Quarry LP purchased a new stake in LivaNova in the third quarter worth about $36,000. Finally, EverSource Wealth Advisors LLC grew its holdings in LivaNova by 998.4% in the second quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock worth $32,000 after purchasing an additional 639 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

LivaNova Trading Down 0.6%

NASDAQ LIVN opened at $78.26 on Thursday. LivaNova has a fifty-two week low of $48.82 and a fifty-two week high of $85.76. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.45. The stock has a 50 day simple moving average of $80.52 and a two-hundred day simple moving average of $72.00. The stock has a market cap of $4.31 billion, a P/E ratio of 23.15 and a beta of 0.86.

LivaNova (NASDAQ:LIVN) last posted its earnings results on Thursday, August 6th. The company reported $1.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.09 by $0.17. LivaNova had a return on equity of 16.35% and a net margin of 12.82%.The firm had revenue of $390.59 million for the quarter, compared to analysts’ expectations of $380.50 million. During the same period in the previous year, the firm earned $1.05 earnings per share. The business’s revenue was up 10.8% compared to the same quarter last year. On average, analysts forecast that LivaNova will post 3.77 earnings per share for the current year.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.